Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Birinapant · TL-32711

Small molecule · Antagonist of XIAP, cIAP1 (BIRC2) and cIAP2 (BIRC3) · developed by TetraLogic Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Birinapant?

Birinapant is a SMAC mimetic and inhibitor of apoptosis proteins (IAP) antagonist that binds to and inhibits XIAP, cIAP1, and cIAP2. By antagonizing IAPs, it restores apoptosis in cancer cells and inactivates NF-kB-mediated survival pathways. It is studied in recurrent ovarian, fallopian tube, and primary peritoneal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TL-32711
Drug type
Small molecule
Targets
XIAP, cIAP1 (BIRC2), cIAP2 (BIRC3)
Mechanism
Antagonist of XIAP, cIAP1 (BIRC2) and cIAP2 (BIRC3)
Pathways
apoptosis, NF-kB signaling
Therapy area
Oncology
Developer
TetraLogic Pharmaceuticals
In trials of
ACOG
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
6O4Z07B57R

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02756130 Phase 1/2 High Grade Fallopian Tube Serous Adenocarcinoma Withdrawn ACOG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma

Other drugs acting on XIAP / BIRC2 / BIRC3

Dasminapant Phase 1/2 GDC-0917 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.